Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Analysts write off Dimension’s lead program after seeing weak data on hemophilia B, shares plunge
9 years ago
Pharma
Eli Lilly shutters the last PhIII sola study, certain of failure
9 years ago
R&D
Pfizer prunes three drugs from its pipeline; Astellas in-licenses ear drug
9 years ago
News Briefing
Trump scolds pharma execs, demanding lower prices, more US manufacturing while promising to slash FDA regs
9 years ago
Pharma
Tenax endures (another) clinical catastrophe as its PhIII flops, shares blitzed
9 years ago
R&D
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
9 years ago
Pharma
Another top Genentech exec gets poached, this time taking the helm at CAR-T player Bellicum
9 years ago
People
Big Pharma CEOs get a face-to-face with Trump and a shot at a negotiated cease fire
9 years ago
Bioregnum
Opinion
After a PhII catastrophe wiped out a billion dollars in market cap, Seres is looking for a do-over
9 years ago
R&D
uniQure wins a BTD for hemophilia B therapy; Allergan scores sNDA for Avycaz
9 years ago
News Briefing
Microcap biotech Ocera craters on a PhIIb failure for hepatic encephalopathy
9 years ago
R&D
FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies
9 years ago
R&D
China
Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front
9 years ago
Pharma
Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford
9 years ago
Financing
R&D
Biotech execs slam Trump’s travel ban, counting the high cost to a global industry
9 years ago
Pharma
Regulus ordered to remain in limbo as FDA refuses to lift hold, demanding more data on lead drug
9 years ago
R&D
Novan’s shares in meltdown following "discordant" PhIII studies of a new acne drug
9 years ago
R&D
Ouch: Eli Lilly is walking away from Adocia deal and its ultra-fast insulin — for the second time
9 years ago
R&D
Highland who? Biotech gets a $200M war chest to crack the US ADHD market
9 years ago
R&D
Jounce’s Cinderella story now includes a $102M IPO chapter
9 years ago
Financing
Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round
9 years ago
News Briefing
M&A is off to a hot start in 2017; Too bad we can't say the same for gender parity
9 years ago
Bioregnum
Opinion
Singapore investors at Temasek grab an $800M stake in Google’s Verily
9 years ago
Financing
Venrock stocks up on $450M Fund 8 as it prepares a new string of biotech deals
9 years ago
Financing
First page
Previous page
1132
1133
1134
1135
1136
1137
1138
Next page
Last page